Dulcolax tab. p / o ksh / sol. 5mg # 30
Category
Preparations for the gastrointestinal tract
Scope of the drug
General
Release form
Tablet
Manufacturer country
France
Package quantity, pcs
thirty
Release form, composition and packaging
Enteric-coated tablets of beige-yellow color, round, biconvex, with an even, smooth, shiny surface and a white core.
1 tab.
bisacodyl 5 mg
corn starch - 8.3 mg, glycerol 85% - 0.2 mg, soluble corn starch - 1.5 mg, lactose - 34.9 mg, magnesium stearate - 0.1 mg.
The composition of the enteric coating: sucrose - 23.3819 mg, talc - 16.1608 mg, acacia gum - 1.9354 mg, titanium dioxide - 0.3995 mg, copolymer of methacrylic acid and methyl methacrylate (1: 2) (Eudragit S100) - 2.2147 mg, copolymer of methacrylic acid (methyl methacrylate) 1: 1) (Eudragit L100) - 0.9866 mg, castor bean seed oil (castor oil) - 0.9762 mg, magnesium stearate - 3.8225 mg, macrogol (polyethylene glycol) 6000 - 0.0462 mg, iron dye yellow oxide (E172) - 0.0657 mg, white beeswax - 0.0015 mg, carnauba wax - 0.003 mg, shellac - 0.006 mg.
10 pieces.
- blisters (3) - cardboard packs.
pharmachologic effect
Laxative drug derived from diphenylmethane.
As a local laxative with an antiresorptive effect, bisacodyl, after hydrolysis in the colon, increases the secretion of water and electrolytes in the colon, accelerates and increases its peristalsis.
This leads to the stimulation of the act of defecation, a decrease in the evacuation time and softening of the stool.
The time for the development of the laxative effect of the drug is 6-12 hours.
Bisacodyl, as a laxative at the level of the colon, stimulates the natural evacuation process in the lower gastrointestinal tract.
Therefore, bisacodyl has no effect on the digestion or absorption of high-calorie foods or essential nutrients in the small intestine.
Pharmacokinetics
Absorption and distribution
Absorption is negligible.
Enteric-coated tablets are resistant to the action of gastrointestinal juice.
Bisacodyl is released in the colon to form the active metabolite, bis- (p-hydroxyphenyl) -pyridyl-2-methane, which is irritating to the colon mucosa.
Cmax of the active metabolite in plasma after taking the drug is achieved after 4-10 hours, the laxative effect develops after 6-12 hours. There is no relationship between the laxative effect of bisacodyl and the concentration of the active metabolite in plasma.
Metabolism and excretion
The drug is almost completely metabolized in the intestinal wall and liver to inactive glucuronide.
Metabolism occurs under the action of enzymes in the mucous membrane of the large intestine.
T1 / 2 is about 16.5 hours. The active metabolite is excreted mainly in the feces (up to 51.8%), about 10.5% is excreted in the urine.
Indications for use
As a laxative in the following cases:
- constipation caused by hypotension of the colon (including chronic)
- preoperative preparation, postoperative treatment
- preparation for instrumental and X-ray examinations
- medical conditions requiring relief of bowel movements.
Contraindications for use
- intestinal obstruction
- obstructive bowel disease
- acute diseases of the abdominal organs, including appendicitis
- acute inflammatory bowel disease
- severe abdominal pain associated with nausea and vomiting, which may be a symptom of a more severe condition
- severe dehydration
- children under 4 years old
- hypersensitivity to bisacodyl or excipients.
One tablet (5 mg) contains 33.2 mg of lactose.
The maximum recommended daily dose of tablets for adults and children over 10 years of age for the treatment of constipation and for x-ray examination contains 66.4 mg and 132.8 mg of lactose, respectively.
Patients with rare hereditary galactose intolerance, for example, ha
Name ENG
DULCOLAX
Clinical and pharmacological group
Laxative drug that stimulates intestinal motility
ATX code
Bisacodyl
Dosage
5mg
Structure
Active ingredients: bisacodyl 5 mg.
Excipients: corn starch - 8.3 mg, glycerol 85% - 0.2 mg, soluble corn starch - 1.5 mg, lactose - 34.9 mg, magnesium stearate - 0.1 mg.
The composition of the enteric shell: sucrose - 23.3819 mg, talc - 16.1608 mg, acacia gum - 1.9354 mg, titanium dioxide - 0.3995 mg, copolymer of methacrylic acid and methyl methacrylate (1: 2) (Eudragit S100) - 2 , 2147 mg, copolymer of methacrylic acid and methyl methacrylate (1: 1) (Eudragit L100) - 0.9866 mg, castor bean seed oil (castor oil) - 0.9762 mg, magnesium stearate - 3.8225 mg, macrogol (polyethylene glycol) 6000 - 0.0462 mg, iron dye yellow oxide (E172) - 0.0657 mg, white beeswax - 0.0015 mg, carnauba wax - 0.003 mg, shellac - 0.006 mg.
Indications
As a laxative in the following cases: - constipation caused by hypotension of the large intestine (including chronic), - preoperative preparation, postoperative treatment, preparation for instrumental and X-ray examinations, medical conditions requiring easier bowel movements.
INN / Active ingredient
bisacodyl
Contraindications
Hypersensitivity to bisacodyl or excipients
intestinal obstruction
obstructive bowel disease
acute diseases of the abdominal organs, including appendicitis
acute inflammatory bowel disease
severe abdominal pain associated with nausea and vomiting, which may be a symptom of a more severe condition
severe dehydration
children under 4 years of age
one tablet (5 mg) contains 33.2 mg of lactose.
The maximum recommended daily dose of tablets for adults and children over 10 years of age for the treatment of constipation and for x-ray examination contains 66.4 mg and 132.8 mg of lactose, respectively.
Patients with rare hereditary galactose intolerance, such as galactosemia, should not take the drug
one tablet (5 mg) contains 23.4 mg of sucrose.
The maximum recommended daily dose of tablets for adults and children over 10 years of age for the treatment of constipation and for X-ray examination contains 46.8 mg and 93.6 mg of sucrose, respectively.
Patients with rare hereditary fructose intolerance should not take the drug.
With caution: the drug should be prescribed to patients with hepatic and / or renal insufficiency.
Storage conditions and periods
In a dry place, at a temperature not exceeding 25 degrees.
Expiration date: 3 years
Specifications
Category
Preparations for the gastrointestinal tract
Scope of the drug
General
Release form
Tablet
Manufacturer country
France
Package quantity, pcs
thirty
Scope of application
Gastroenterology
Minimum age from
4 years old
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Boehringer ingelheim
The amount of the dosage form in the primary package
10 pieces.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Laxative
Anatomical and therapeutic characteristics
A06AB02 Bisacodyl
Dosage form
Enteric-coated tablets
The target audience
Children
Dosage (volume) of the substance in the preparation
bisacodyl 5 mg
Expiration date in days
1095
Package weight, g
thirty
Mode of application
:
The tablets are taken orally with plenty of liquid.
For constipation, adults and children over 10 years old are prescribed 1-2 tablets.
(5-10 mg).
It is recommended to start with the lowest dose.
In order to achieve regular bowel movements, the dose may be increased to the maximum recommended (10 mg).
Do not exceed the maximum recommended daily dose.
Children aged 4-10 years old - 1 tab.
(With 5 mg).
Do not exceed the maximum recommended daily dose (5 mg).
To obtain a laxative effect in the morning, it is recommended to take the drug the night before.
Information on technical characteristics, delivery set, country of manufacture